Tuesday, July 20, 2021 1:16:26 PM
"13D nominees took"--lets see if this is correct
Errico STARTED the company (no takeover nonsense)
The company ERCO did studies. Then trials. Then Euro approval. Saw potential in other uses. Did trials for "clusters". Did trials for "migraines". Got FDA approval for both. After those approvals they went public to Nasdaq. Since, they have gotten more approvals for "preventative" uses to go with therapeutic.
I think where some (that don't really understand-or don't want to) see the ERCO stock after their IPO then look at the price after. If that is on the founder of a company that still buys his own companys' stock so be it. I don't hold nodder responsible for collapse of cydy stock from $10. Is the kodak board the reason their stock shot up, gamestop board made their stock shoot up--I don't believe that--some do??
So a guy takes a product--develops it--gets it thru studies--thru trials--gets FDA approval--gets his company on NASDAQ. This is what people call a "takeover" and a run into the ground?? wow
get product developed--get product thru trials--get FDA approval for product--get Nasdaq --get insider purchasing their own company stock
Y E S====>>>> PLEASE
https://fintel.io/n/us/ecor/errico-thomas-j
Errico STARTED the company (no takeover nonsense)
The company ERCO did studies. Then trials. Then Euro approval. Saw potential in other uses. Did trials for "clusters". Did trials for "migraines". Got FDA approval for both. After those approvals they went public to Nasdaq. Since, they have gotten more approvals for "preventative" uses to go with therapeutic.
I think where some (that don't really understand-or don't want to) see the ERCO stock after their IPO then look at the price after. If that is on the founder of a company that still buys his own companys' stock so be it. I don't hold nodder responsible for collapse of cydy stock from $10. Is the kodak board the reason their stock shot up, gamestop board made their stock shoot up--I don't believe that--some do??
So a guy takes a product--develops it--gets it thru studies--thru trials--gets FDA approval--gets his company on NASDAQ. This is what people call a "takeover" and a run into the ground?? wow
get product developed--get product thru trials--get FDA approval for product--get Nasdaq --get insider purchasing their own company stock
Y E S====>>>> PLEASE
https://fintel.io/n/us/ecor/errico-thomas-j
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
